Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com

Please find enclosed a Press Release on

"Dr. Reddy's Laboratories announces the launch of

Pregabalin Capsules in the U.S. Market"

This is for your information.

CC:- New York Stock Exchange Inc.(Stock Code :RDY)

Reddy's Laboratories announces the launch of

Pregabalin Capsules in the U.S. Market

Hyderabad, India and Princeton, NJ, USA. July 30, 2019 -

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as

"Dr. Reddy's") today announced the launch of Pregabalin Capsules a therapeutic equivalent generic version of

Lyrica (pregabalin) Capsules approved by the U.S. Food and Drug Administration (USFDA).

The Lyrica (pregabalin) Capsules brand had U.S.

sales of approximately $5,462 million MAT for the most recent twelve months ending in May 2019 according to IQVIA Health*.

Dr. Reddy's Pregabalin Capsules are available in 25 mg,

50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg capsules in bottle count sizes of 90. This is also a controlled substance

Lyrica is a trademark of C.P. PHARMACEUTICALS INTERNATIONAL

*IQVIA Retail and Non-Retail MAT May 2019.

About Dr. Reddy's: Dr. Reddy's Laboratories

Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative

medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics

and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical

services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular,

diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets

include - USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements

of future expectations and other forward-looking statements that are based on the management's current views and assumptions

and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially

from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the

words "may", "will", "should", "expects", "plans", "intends", "anticipates",

"believes", "estimates", "predicts", "potential", or "continue" and similar expressions

identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements

due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency

exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity

levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and

in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration

The company assumes no obligation to update any information